

Supplementary information

Exo70 is an independent prognostic factor in colon cancer


Li Xiao^{1,2,ξ}, Kaifeng Zheng^{1,ξ}, Xia Lv², Jihuan Hou¹, Liang Xu¹, Yujie Zhao¹, Fei Song¹, Yaqiong Fan¹, Hanwei Cao¹, Wenqing Zhang¹, Xiaoting Hong¹, Yan-yan Zhan^{1,*}, and Tianhui Hu^{1,*}

¹Cancer Research Center, Xiamen University Medical College, Xiamen 361102, Fujian Province, PR China


²Department of Oncology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, Fujian Province, PR China

^ξThese authors have contributed equally to this work

***Correspondence to:** Tianhui Hu, e-mail: thu@xmu.edu.cn or Yan-yan Zhan, email: yyzhan@xmu.edu.cn




Supplementary Figure S1. Verification of the specificity of anti-Exo70 antibody by immunohistochemistry on formalin-fixed and paraffin-embedded (FFPE) EXO70 knocking-down colon cancer cell pellet slide. (a-b) RKO cells were transfected with shRNA (S1 mentioned in Fig. 5) targeting Exo70, and then subjected to western blot (a) and immunohistochemical staining (b) using anti-Exo70 antibody (Abcam, ab57402).



Supplementary Figure S2. Expression levels of Exo70 isoforms during EMT in colon cancer cells. (a-c) HCT116, RKO and SW620 cells were treated with human TGF-β1 (20 ng/mL) for 72h, and then subjected to qRT-PCR. ** $P < 0.01$, *** $P < 0.001$.

Supplementary Figure S3. Original western blots



Supplementary Figure S4. Original western blots

